1100TiP - An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)

Y.-J Bang,L.W Goff,H Wasserstrom,J Yang,G Mi,M Karasarides,M Reck

doi:10.1093/annonc/mdw378.53

1100TiP - An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)

Y.-J Bang, L.W Goff + Show 5 more

Open Access

https://doi.org/10.1093/annonc/mdw378.53

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2016
Citations: 1	License type: publisher-specific-oa

Affiliation: Eli Lilly (United States), AstraZeneca (United States), LungenClinic Grosshansdorf

#Study Of Ramucirumab #Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1100TiP - An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)

Full Text